1.甘肃省肿瘤医院 兰州 730050
牛瑞军,男,1990年1月出生,2013年毕业于南华大学核技术专业,现甘肃省肿瘤医院放疗科医学物理师,从事放射治疗医学物理工作,工程师,E-mail: niuruijungs@163.com
高力英,主任医师,E-mail: lygaolanzhou@163.com
魏世鸿,主任医师,E-mail: weishihong100@163.com
扫 描 看 全 文
牛瑞军, 祁月潇, 陶娜, 等. 不同硅胶补偿方式对乳腺癌根治术后调强放射治疗计划剂量学差异分析[J]. 辐射研究与辐射工艺学报, 2023,41(3):030307.
NIU Ruijun, QI Yuexiao, TAO Na, et al. Dosimetric difference analysis of various bolus regimens in post-mastectomy intensity modulated radiotherapy[J]. Journal of Radiation Research and Radiation Processing, 2023,41(3):030307.
牛瑞军, 祁月潇, 陶娜, 等. 不同硅胶补偿方式对乳腺癌根治术后调强放射治疗计划剂量学差异分析[J]. 辐射研究与辐射工艺学报, 2023,41(3):030307. DOI: 10.11889/j.1000-3436.2022-0083.
NIU Ruijun, QI Yuexiao, TAO Na, et al. Dosimetric difference analysis of various bolus regimens in post-mastectomy intensity modulated radiotherapy[J]. Journal of Radiation Research and Radiation Processing, 2023,41(3):030307. DOI: 10.11889/j.1000-3436.2022-0083.
分析不同硅胶补偿方式对乳腺癌根治术后调强放射治疗计划剂量学的影响;应用Oncentra 4.1放射治疗计划系统对38例乳腺癌根治术后患者设计三组放射治疗计划,分别为全程垫5 mm(5 mm_all)、半程垫5 mm(5 mm_half)、半程垫10 mm(10 mm_half)硅胶计划,处方剂量为50 Gy/25 次(2 Gy/次),其中半程计划前15次垫硅胶,后10次不垫硅胶,三组计划设置相同的照射野及目标函数,采用逆向调强进行优化,比较靶区、皮肤及危及器官的剂量学差异,正常组织并发症概率(Normal tissue complication probability NTCP)差异;5 mm_all计划所得CTV的,D,2,、,D,50,、,V,90,、,V,95,、,V,115,均优于其他两组所得且,D,50,、,V,90,有显著的统计学差异(,p<,0.05);PTV的,D,2,、,D,50,、,D,95,、,D,98,、,D,max,、,V,90,、,V,95,、,V,115,、均匀性指数(HI)及适形度指数(CI)均优于其他两组所得,且,D,50,、,D,95,、,D,98,、,V,90,、,V,95,及HI均有显著的统计学差异(,p<,0.05);5 mm_all所得食管的,V,45,、心脏的,V,30,、,V,40,、,D,max,,肱骨头的,V,50,、,D,max,、,D,mean,,左肺的,V,20,、,V,30,、,D,max,,甲状腺的,D,max,、,D,mean,,气管的,D,mean,均小于其他组所得,但无显著的统计学差异,5 mm_all所得皮肤的,V,40,、,V,45,、,V,50,、,D,mean,均优于其他组所得,且均有显著的统计学差异(,p<,0.05),高剂量区,V,55,及热点,D,max,均低于其他组计划所得,三组计划总的机器调数(MU)有显著的统计学差异(,p<,0.05)且5 mm_all组总MU最低;5 mm_all组计划NTCP略优于其他组且有显著的统计学差异(,p<,0.05);在乳腺癌根治术后放射治疗计划设计中,全程垫5 mm硅胶能提高皮肤及靶区的剂量,提高靶区的均匀性指数和适形度指数,减少靶区及皮肤的高剂量区和热点,降低危及器官的受量,而且大幅度地减小治疗总MU减轻加速器负荷,缩短了治疗时间;同时,通过生物学模型的计算可知降低NTCP。
The study aimed to analyze and compare dosimetric differences with various thicknesses and frequencies of bolus in post-mastectomy intensity-modulated radiotherapy. Based on the Oncentra4.1 treatment planning system, Thirty-eight post-mastectomy patients were selected randomly between 2017 and 2021. Three sets of simulated treatment planning with 5_mm all, 5_mm half, and 10_mm half virtual boluses were formed. A total prescribed dose of 50 Gy regimen was delivered in 25 fractions over 5 weeks, in which half-time bolus was used for 15 out of 25 fractions. The dosimetric parameters of target areas, skin, and organs at risk were compared. Furthermore, normal tissue complication probability (NTCP) was evaluated for the skin. Regarding the ,D,2,D,50,V,90,V,95, and ,V,115, of the clinical target volume, the 5_mm all bolus group was prominently better than other groups, and the ,D,50, and ,V,90, of the clinical target volumes were statistically significant (,p,<, 0.05). Regarding the ,D,2,D,50,D,95,D,98,D,max,V,90,V,95,V,115, homogeneity index (HI), and conformity index of the planning target volume, the 5_mm thick bolus group was prominently better than other groups, and the ,D,50,D,95,D,98,V,90,V,95, and HI of the clinical target volumes were statistically significant (,p,<, 0.05). For organs at risk, there was no statistical significance for the three planning groups, but the 5_mm all bolus group was prominently better than other groups in the ,V,45, of the esophagus,V,30,V,40, and ,D,max, of the heart,V,50,D,max, and ,D,mean, of the humerus head,V,20,V,30, and ,D,max, of the left lung,D,max, and ,D,mean, of the thyroid, and ,D,mean, of the trachea. Calculated with the 5_mm all bolus, the mean dose,V,40,V,45, and ,V,50, for the skin structure, were all higher than other bolus regimens, while the dose maxima (Skin,max, and ,V,55,) were all lower than others. Regarding the skin radiobiological evaluation, the NTCP of the 5_mm all bolus group was prominently better than other groups and was statistically significant (,p,<, 0.05). Besides, the monitor unit of 5_mm all bolus regimen was the minimum compared with other groups and was statistically significant (,p,<, 0.05). Therefore, the 5_mm all bolus group can not only improve the dose but also reduce the hot dose of skin and target volume, as well as reduce the NTCP. Our study provides a clinical reference in the delivery of post-mastectomy radiotherapy.
乳腺癌根治术调强放射治疗硅胶剂量学差异分析
BreastPost-mastectomy intensity modulated radiotherapyBolusDosimetric difference analysis
Harbeck N, Gnant M. Breast cancer[J]. The Lancet, 2017, 389(10074): 1134-1150. DOI: 10.1016/s0140-6736(16)31891-8http://dx.doi.org/10.1016/s0140-6736(16)31891-8.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet (London, England), 2005, 366(9503): 2087-2106. DOI: 10.1016/S0140-6736(05)67887-7http://dx.doi.org/10.1016/S0140-6736(05)67887-7.
Schuck A, Könemann S, Heinen K, et al. Microscopic residual disease is a risk factor in the primary treatment of breast cancer[J]. Strahlentherapie Und Onkologie, 2002, 178(6): 307-313. DOI: 10.1007/s00066-002-0950-7http://dx.doi.org/10.1007/s00066-002-0950-7.
Gez E, Assaf N, Bar-Deroma R, et al. Postmastectomy electron-beam chest-wall irradiation in women with breast cancer[J]. International Journal of Radiation Oncology, Biology, Physics, 2004, 60(4): 1190-1194. DOI: 10.1016/j.ijrobp.2004.05.036http://dx.doi.org/10.1016/j.ijrobp.2004.05.036.
Noël G, Mazeron J J. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials[J]. Cancer Radiother, 2001, 5(1): 92-94. DOI: 10.1016/s1278-3218(00)00058-5http://dx.doi.org/10.1016/s1278-3218(00)00058-5.
Klass O, Walker M, Siebach A, et al. Prospectively gated axial CT coronary angiography: comparison of image quality and effective radiation dose between 64- and 256-slice CT[J]. European Radiology, 2010, 20(5): 1124-1131. DOI: 10.1007/s00330-009-1652-7http://dx.doi.org/10.1007/s00330-009-1652-7.
Feuvret L, Noël G, Mazeron J J, et al. Conformity index: a review[J]. International Journal of Radiation Oncology, Biology, Physics, 2006, 64(2): 333-342. DOI: 10.1016/j.ijrobp.2005.09.028http://dx.doi.org/10.1016/j.ijrobp.2005.09.028.
Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)[J]. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft, 2012, 188(1): 97-99. DOI: 10.1007/s00066-011-0015-xhttp://dx.doi.org/10.1007/s00066-011-0015-x.
Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose[J]. Medical Physics, 1997, 24(1): 103-110. DOI: 10.1118/1.598063http://dx.doi.org/10.1118/1.598063.
Luxton G, Keall P J, King C R. A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD)[J]. Physics in Medicine and Biology, 2008, 53(1): 23-36. DOI: 10.1088/0031-9155/53/1/002http://dx.doi.org/10.1088/0031-9155/53/1/002.
Uematsu M, Shioda A, Tahara K, et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience[J]. Cancer, 1998, 82(6): 1062-1070. DOI: 10.1002/(sici)1097-0142(19980315)82: 61062: aid-cncr8>3.0.co;2-ghttp://dx.doi.org/10.1002/(sici)1097-0142(19980315)82:61062:aid-cncr8>3.0.co;2-g.
Shiau A C, Chiu M C, Chen T H, et al. Surface and superficial dose dosimetric verification for postmastectomy radiotherapy[J]. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists, 2012, 37(4): 417-424. DOI: 10.1016/j.meddos.2012.03.005http://dx.doi.org/10.1016/j.meddos.2012.03.005.
Ercan T, İğdem Ş, Alço G, et al. Dosimetric comparison of field in field intensity-modulated radiotherapy technique with conformal radiotherapy techniques in breast cancer[J]. Japanese Journal of Radiology, 2010, 28(4): 283-289. DOI: 10.1007/s11604-010-0423-3http://dx.doi.org/10.1007/s11604-010-0423-3.
Lancet T. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group[J]. Lancet, 2000, 355(9217): 1757-1770. DOI: 10.1016/S0140-6736(00)02263-7http://dx.doi.org/10.1016/S0140-6736(00)02263-7.
Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials[J]. Radiotherapy and Oncology, 2007, 82(3): 247-253. DOI: 10.1016/j.radonc.2007. 02.001http://dx.doi.org/10.1016/j.radonc.2007.02.001.
Katz A, Strom E A, Buchholz T A, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2000, 18(15): 2817-2827. DOI: 10.1200/JCO.2000.18. 15.2817http://dx.doi.org/10.1200/JCO.2000.18.15.2817.
Vu T T, Pignol J P, Rakovitch E, et al. Variability in radiation oncologists' opinion on the indication of a bolus in post-mastectomy radiotherapy: an international survey[J]. Clinical Oncology (Royal College of Radiologists (Great Britain)), 2007, 19(2): 115-119. DOI: 10.1016/j.clon.2006.10.004http://dx.doi.org/10.1016/j.clon.2006.10.004.
Soong I S, Yau T K, Ho C M,et al. Post-mastectomy radiotherapy after immediate autologous breast reconstruction in primary treatment of breast cancers[J]. Clinical Oncology, 2004, 16(4): 283-289. DOI: 10.1016/j.clon.2004.01.007http://dx.doi.org/10.1016/j.clon.2004.01.007.
Gerbi B J, Meigooni A S, Khan F M. Dose buildup for obliquely incident photon beams[J]. Medical Physics, 1987, 14(3): 393-399. DOI: 10.1118/1.596055http://dx.doi.org/10.1118/1.596055.
Fisher J, Scott C, Stevens R, et al. Randomized phase III study comparing best supportive care to biafine as a prophylactic agent for radiation-induced skin toxicity for women undergoing breast irradiation: radiation therapy oncology group (RTOG) 97-13[J]. International Journal of Radiation Oncology*Biology*Physics, 2000, 48(5): 1307-1310. DOI: 10.1016/S0360-3016(00)00782-3http://dx.doi.org/10.1016/S0360-3016(00)00782-3.
Fernando I N,Ford H T,Powles T J,et al. Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital[J]. Clinical Oncology, 1996, 8(4): 226-233. DOI: 10.1016/S0936-6555(05)80657-0http://dx.doi.org/10.1016/S0936-6555(05)80657-0.
Moody A M, Mayles W P, Bliss J M, et al. The influence of breast size on late radiation effects and association with radiotherapy dose inhomogeneity[J]. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 1994, 33(2): 106-112. DOI: 10.1016/0167-8140(94)90063-9http://dx.doi.org/10.1016/0167-8140(94)90063-9.
邹勤舟, 魏贤顶, 赵于天, 等. 乳腺癌术后胸壁和锁骨上区整体调强剂量学探讨[J]. 实用临床医药杂志, 2012, 16(23): 32-35.
ZOU Qinzhou, WEI Xianding, ZHAO Yutian, et al. Irradiation of the chest wall and regional nodes as an integrated volume with IMRT for breast cancer after mastectomy: from dosimetry to clinical observation[J]. Journal of Clinical Medicine in Practice, 2012, 16(23): 32-35.
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation[J]. International Journal of Radiation Oncology*Biology*Physics, 1991, 21(1): 109-122. DOI: 10.1016/0360-3016(91)90171-yhttp://dx.doi.org/10.1016/0360-3016(91)90171-y.
Mayadev J, Einck J, Elson S, et al. Practice patterns in the delivery of radiation therapy after mastectomy among the University of California Athena Breast Health Network[J]. Clinical Breast Cancer, 2015, 15(1): 43-47. DOI: 10.1016/j.clbc.2014.07.005http://dx.doi.org/10.1016/j.clbc.2014.07.005.
0
浏览量
10
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构